Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article; Review
- Language: English
- [Eur J Nucl Med Mol Imaging] 2021 Nov; Vol. 48 (12), pp. 4028-4041. <i>Date of Electronic Publication: </i>2021 Mar 06.
- MeSH Terms: Prostatic Neoplasms, Castration-Resistant* / radiotherapy ; Quality of Life* ; Dipeptides ; Heterocyclic Compounds, 1-Ring ; Humans ; Male ; Prognosis ; Treatment Outcome
- References: Beheshti M, Manafi-Farid R, Geinitz H, Vali R, Loidl W, Mottaghy FM, et al. Multiphasic (68)Ga-PSMA PET/CT in the detection of early recurrence in prostate cancer patients with a PSA level of less than 1 ng/mL: a prospective study of 135 patients. J Nucl Med. 2020;61:1484–90. https://doi.org/10.2967/jnumed.119.238071 . (PMID: 10.2967/jnumed.119.23807132060214) ; National Cancer Institute. Surveillance E, and End Results Program. Cancer Stat Facts: Prostate Cancer. 2010–2016. Available from: https://seer.cancer.gov/statfacts/html/prost.html . Accessed 18 Sep 2020. ; Silberstein JL, Pal SK, Lewis B, Sartor O. Current clinical challenges in prostate cancer. Transl Androl Urol. 2013;2:122–36. https://doi.org/10.3978/j.issn.2223-4683.2013.09.03 . (PMID: 10.3978/j.issn.2223-4683.2013.09.03268167354708189) ; Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, Bogemann M, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-020-04797-9 . ; Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:471–95. https://doi.org/10.1007/s00259-017-3882-2 . (PMID: 10.1007/s00259-017-3882-229282518) ; Ahmadzadehfar H, Aryana K, Pirayesh E, Farzanehfar S, Assadi M, Fallahi B, et al. The Iranian Society of Nuclear Medicine practical guideline on radioligand therapy in metastatic castration-resistant prostate cancer using 177Lu-PSMA. Iran J Nucl Med. 2018;26:2–8. ; Fallahi B, Khademi N, Karamzade-Ziarati N, Fard-Esfahani A, Emami-Ardekani A, Farzanefar S, et al. 99mTc-PSMA SPECT/CT versus 68Ga-PSMA PET/CT in the evaluation of metastatic prostate cancer. Clin Nucl Med. 2020. https://doi.org/10.1097/rlu.0000000000003410 . ; Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol. 2003;170:1717–21. https://doi.org/10.1097/01.ju.0000091655.77601.0c . (PMID: 10.1097/01.ju.0000091655.77601.0c14532761) ; Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010;51:1293–300. https://doi.org/10.2967/jnumed.110.076174 . (PMID: 10.2967/jnumed.110.07617420660376) ; Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, et al. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med. 2005;46:634–41. (PMID: 15809486) ; Pandit-Taskar N, O’Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, et al. First-in-human imaging with 89Zr-Df-IAB2M anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion uptake. J Nucl Med. 2016;57:1858–64. https://doi.org/10.2967/jnumed.116.176206 . (PMID: 10.2967/jnumed.116.176206275164505450345) ; Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883–91. https://doi.org/10.2967/jnumed.112.104661 . (PMID: 10.2967/jnumed.112.10466123203246) ; Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17:565–74. https://doi.org/10.1007/s11307-015-0850-8 . (PMID: 10.1007/s11307-015-0850-8258968144531836) ; Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–705. https://doi.org/10.2967/jnumed.115.161299 . (PMID: 10.2967/jnumed.115.16129926294298) ; Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga-and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169–76. https://doi.org/10.2967/jnumed.115.158550 . (PMID: 10.2967/jnumed.115.15855026089548) ; Pandit-Taskar N, O’Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, et al. A phase I/II study for analytic validation of 89Zr-J591 immunoPET as a molecular imaging agent for metastatic prostate cancer. Clin Cancer Res. 2015;21:5277–85. https://doi.org/10.1158/1078-0432.CCR-15-0552 . (PMID: 10.1158/1078-0432.CCR-15-0552261755414668231) ; Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kurpig S, Eppard E, et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [(177)Lu]Lu-PSMA-617. Eur J Nucl Med Mol Imaging. 2017;44:1448–54. https://doi.org/10.1007/s00259-017-3716-2 . (PMID: 10.1007/s00259-017-3716-228488028) ; Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. An overview of targeted alpha therapy with (225)Actinium and (213)Bismuth. Curr Radiopharm. 2018;11:200–8. https://doi.org/10.2174/1874471011666180502104524 . (PMID: 10.2174/1874471011666180502104524297329986237921) ; Sathekge M, Knoesen O, Meckel M, Modiselle M, Vorster M, Marx S. 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1099–100. https://doi.org/10.1007/s00259-017-3657-9 . (PMID: 10.1007/s00259-017-3657-9282557955397654) ; Heck MM, Tauber R, Schwaiger S, Retz M, D’Alessandria C, Maurer T, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with (177)Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 2019;75:920–6. https://doi.org/10.1016/j.eururo.2018.11.016 . (PMID: 10.1016/j.eururo.2018.11.01630473431) ; Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–33. https://doi.org/10.1016/S1470-2045(18)30198-0 . (PMID: 10.1016/S1470-2045(18)30198-029752180) ; Kim YJ, Kim YI. Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer: a meta-analysis. Clin Nucl Med. 2018;43:728–34. https://doi.org/10.1097/RLU.0000000000002210 . (PMID: 10.1097/RLU.000000000000221030059428) ; Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schafers M, Essler M, et al. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2018;45:12–9. https://doi.org/10.1007/s00259-017-3848-4 . (PMID: 10.1007/s00259-017-3848-429026946) ; Ferdinandus J, Eppard E, Gaertner FC, Kurpig S, Fimmers R, Yordanova A, et al. Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617. J Nucl Med. 2017;58:312–9. https://doi.org/10.2967/jnumed.116.178228 . (PMID: 10.2967/jnumed.116.17822827587707) ; Giraudet A. Radionuclide therapy targeting PSMA for the treatment of metastatic prostate cancer: current point of view and ways of improvement. Médecine Nucléaire. 2019;43:275–9. (PMID: 10.1016/j.mednuc.2019.03.003) ; Yadav MP, Ballal S, Bal C, Sahoo RK, Damle NA, Tripathi M, et al. Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients. Clin Nucl Med. 2020;45:19–31. https://doi.org/10.1097/RLU.0000000000002833 . (PMID: 10.1097/RLU.000000000000283331789908) ; Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. Lutetium-177 PSMA radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016:jnumed:115.168443. https://doi.org/10.2967/jnumed.115.168443 . ; Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90. https://doi.org/10.2967/jnumed.116.183194 . (PMID: 10.2967/jnumed.116.18319427765862) ; Yordanova A, Linden P, Hauser S, Meisenheimer M, Kurpig S, Feldmann G, et al. Outcome and safety of rechallenge [(177)Lu]Lu-PSMA-617 in patients with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1073–80. https://doi.org/10.1007/s00259-018-4222-x . (PMID: 10.1007/s00259-018-4222-x30474706) ; Bräuer A, Grubert LS, Roll W, Schrader AJ, Schäfers M, Bögemann M, et al. 177 Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1663–70. https://doi.org/10.1007/s00259-017-3751-z . (PMID: 10.1007/s00259-017-3751-z28624848) ; Ferdinandus J, Violet J, Sandhu S, Hicks RJ, Ravi Kumar AS, Iravani A, et al. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. Eur J Nucl Med Mol Imaging. 2020;47:2322–7. https://doi.org/10.1007/s00259-020-04723-z . (PMID: 10.1007/s00259-020-04723-z32140802) ; Yordanova A, Linden P, Hauser S, Feldmann G, Brossart P, Fimmers R, et al. The value of tumor markers in men with metastatic prostate cancer undergoing [(177) Lu]Lu-PSMA therapy. Prostate. 2020;80:17–27. https://doi.org/10.1002/pros.23912 . (PMID: 10.1002/pros.2391231579967) ; Gafita A, Heck M, Rauscher I, Tauber R, Cala L, Franz C, et al. Early prostate-specific antigen changes and clinical outcome following 177Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer. J Nucl Med. :2020:jnumed. 119.240242. https://doi.org/10.2967/jnumed.119.240242 . ; Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. Clinical outcomes of 177Lu-PSMA radioligand therapy in taxane chemotherapy pretreated and taxane chemotherapy naïve patients with metastatic castration resistant prostate cancer. J Nucl Med:2019:jnumed.118.216820. https://doi.org/10.2967/jnumed.118.216820 . ; Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, et al. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy. Oncotarget. 2017;8:103108–16. https://doi.org/10.18632/oncotarget.21600 . (PMID: 10.18632/oncotarget.21600) ; Grubmüller B, Senn D, Kramer G, Baltzer P, D’Andrea D, Grubmüller KH, et al. Response assessment using 68 Ga-PSMA ligand PET in patients undergoing 177 Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1063–72. https://doi.org/10.1007/s00259-018-4236-4 . (PMID: 10.1007/s00259-018-4236-430569186) ; Gafita A, Calais J, Hui W, Weber M, Rathke H, Esfandiari R, et al. Predictive factors and prediction nomograms for LuPSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer: an international multicentre retrospective study. J Nucl Med. 2020;61:593. (PMID: 10.2967/jnumed.119.240242) ; Derlin T, Sommerlath Sohns JM, Schmuck S, Henkenberens C, von Klot CA, Ross TL, et al. Influence of short-term dexamethasone on the efficacy of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Prostate. 2020;80:619–31. https://doi.org/10.1002/pros.23974 . (PMID: 10.1002/pros.2397432187729) ; Gadot M, Davidson T, Aharon M, Atenafu EG, Malki A, Levartovsky M, et al. Clinical variables associated with PSA response to Lutetium-177-PSMA ([177Lu]-PSMA-617) radionuclide treatment in men with metastatic castration-resistant prostate cancer. Cancers (Basel). 2020;12:1078. https://doi.org/10.3390/cancers12051078 . (PMID: 10.3390/cancers12051078) ; Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, Schlenkhoff CD, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7:12477–88. https://doi.org/10.18632/oncotarget.7245 . (PMID: 10.18632/oncotarget.7245268712854914299) ; Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461–7. https://doi.org/10.1200/JCO.1999.17.11.3461 . (PMID: 10.1200/JCO.1999.17.11.346110550143) ; Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402–18. https://doi.org/10.1200/JCO.2015.64.2702 . (PMID: 10.1200/JCO.2015.64.2702269035794872347) ; Yadav MP, Ballal S, Sahoo RK, Dwivedi SN, Bal C. Radioligand therapy with (177)Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol. 2019;213:275–85. https://doi.org/10.2214/AJR.18.20845 . (PMID: 10.2214/AJR.18.2084530995089) ; Gafita A, Rauscher I, Retz M, Knorr K, Heck M, Wester HJ, et al. Early experience of rechallenge (177)Lu-PSMA radioligand therapy after an initial good response in patients with advanced prostate cancer. J Nucl Med. 2019;60:644–8. https://doi.org/10.2967/jnumed.118.215715 . (PMID: 10.2967/jnumed.118.21571530442756) ; Roll W, Brauer A, Weckesser M, Bogemann M, Rahbar K. Long-term survival and excellent response to repeated 177Lu-prostate-specific membrane antigen 617 radioligand therapy in a patient with advanced metastatic castration-resistant prostate cancer. Clin Nucl Med. 2018;43:755–6. https://doi.org/10.1097/RLU.0000000000002212 . (PMID: 10.1097/RLU.000000000000221230036254) ; Rahbar K, Bogeman M, Yordanova A, Eveslage M, Schafers M, Essler M, et al. Delayed response after repeated (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:243–6. https://doi.org/10.1007/s00259-017-3877-z . (PMID: 10.1007/s00259-017-3877-z29134280) ; Mottet NBJ, Briers E, Bolla M, Bourke L, Cornford P, De Santis M, et al. Guidelines on prostate cancer. Arnhem, The Netherlands: EAU Guidelines Office; 2020. Available from: https://uroweb.org/guideline/prostate-cancer/ . Accessed 9 Sep 2020. ; Suman S, Parghane RV, Joshi A, Prabhash K, Bakshi G, Talole S, et al. Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort. Brit J Radiol. 2019;92:20190380. https://doi.org/10.1259/bjr.20190380 . (PMID: 10.1259/bjr.20190380316000896913363) ; Kulkarni H, Schuchardt C, Singh A, Langbein T, Baum R. Early initiation of Lu-177 PSMA radioligand therapy prolongs overall survival in metastatic prostate cancer. J Nucl Med. 2018;59:supplement 1.529. ; Kesavan M, Turner JH, Meyrick D, Yeo S, Cardaci G, Lenzo NP. Salvage radiopeptide therapy of advanced castrate-resistant prostate cancer with Lutetium-177-labeled prostate-specific membrane antigen: efficacy and safety in routine practice. Cancer Biother Radiopharm. 2018;33:274–81. https://doi.org/10.1089/cbr.2017.2403 . (PMID: 10.1089/cbr.2017.240329989440) ; Rathke H, Giesel FL, Flechsig P, Kopka K, Mier W, Hohenfellner M, et al. Repeated (177)Lu-labeled PSMA-617 radioligand therapy using treatment activities of up to 9.3 GBq. J Nucl Med. 2018;59:459–65. https://doi.org/10.2967/jnumed.117.194209 . (PMID: 10.2967/jnumed.117.19420928798031) ; Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60:517–23. https://doi.org/10.2967/jnumed.118.219352 . (PMID: 10.2967/jnumed.118.21935230291192) ; Seifert R, Seitzer K, Herrmann K, Kessel K, Schafers M, Kleesiek J, et al. Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving (177)Lu-PSMA-617 radioligand therapy. Theranostics. 2020;10:7812–20. https://doi.org/10.7150/thno.47251 . (PMID: 10.7150/thno.47251326850217359095) ; Gunalp B, Emer M, Ozaydin S, Alagoz E, Semra I, Ayan A, et al. Effectiveness of 177Lu PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. J Nucl Med. 2018;59:1478. ; Emmett L, Crumbaker M, Ho B, Willowson K, Eu P, Ratnayake L, et al. Results of a prospective phase 2 pilot trial of (177)Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression. Clin Genitourin Cancer. 2019;17:15–22. https://doi.org/10.1016/j.clgc.2018.09.014 . (PMID: 10.1016/j.clgc.2018.09.01430425003) ; Heinzel A, Boghos D, Mottaghy FM, Gaertner F, Essler M, von Mallek D, et al. (68)Ga-PSMA PET/CT for monitoring response to (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1054–62. https://doi.org/10.1007/s00259-019-4258-6 . (PMID: 10.1007/s00259-019-4258-630697649) ; Gafita A, Calais J, Wang H, Weber M, Rathke H, Kratochwil C, et al. Prognostic markers for overall survival and outcome to LuPSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer. Am J Clin Oncol. 2020:5548. ; Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol. 2016;34:1652–9. https://doi.org/10.1200/JCO.2015.65.7270 . (PMID: 10.1200/JCO.2015.65.7270269513124872320) ; Karamzade-Ziarati N, Manafi-Farid R, Ataeinia B, Langsteger W, Pirich C, Mottaghy FM, et al. Molecular imaging of bone metastases using tumor-targeted tracers. Q J Nucl Med Mol Imaging. 2019;63:136–49. https://doi.org/10.23736/S1824-4785.19.03206-0 . (PMID: 10.23736/S1824-4785.19.03206-031315347) ; Zhuo L, Cheng Y, Pan Y, Zong J, Sun W, Xu L, et al. Prostate cancer with bone metastasis in Beijing: an observational study of prevalence, hospital visits and treatment costs using data from an administrative claims database. BMJ Open. 2019;9:e028214. https://doi.org/10.1136/bmjopen-2018-028214 . (PMID: 10.1136/bmjopen-2018-028214312300196597097) ; Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010;184:162–7. https://doi.org/10.1016/j.juro.2010.03.034 . (PMID: 10.1016/j.juro.2010.03.03420483155) ; Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, et al. Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate. 2014;74:210–6. https://doi.org/10.1002/pros.22742 . (PMID: 10.1002/pros.2274224132735) ; Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. Clinical outcomes of 177lu-psma radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy. J Nucl Med. 2019;60:955–62. https://doi.org/10.2967/jnumed.118.216820 . (PMID: 10.2967/jnumed.118.21682030683770) ; Gravis G, Boher JM, Fizazi K, Joly F, Priou F, Marino P, et al. Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the glass model and development of a novel simplified prognostic model. Eur Urol. 2015;68:196–204. https://doi.org/10.1016/j.eururo.2014.09.022 . (PMID: 10.1016/j.eururo.2014.09.02225277272) ; Rao SR, Snaith AE, Marino D, Cheng X, Lwin ST, Orriss IR, et al. Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer. Br J Cancer. 2017;116:227–36. https://doi.org/10.1038/bjc.2016.402 . (PMID: 10.1038/bjc.2016.40228006818) ; Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014;32:671–7. https://doi.org/10.1200/JCO.2013.52.3696 . (PMID: 10.1200/JCO.2013.52.3696244492313927736) ; Naruse K, Yamada Y, Aoki S, Taki T, Nakamura K, Tobiume M, et al. Lactate dehydrogenase is a prognostic indicator for prostate cancer patients with bone metastasis. Hinyokika Kiyo. 2007;53:287–92. (PMID: 17561711) ; Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20:3972–82. https://doi.org/10.1200/JCO.2002.11.021 . (PMID: 10.1200/JCO.2002.11.02112351594) ; Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46:2536–44. https://doi.org/10.1007/s00259-019-04485-3 . (PMID: 10.1007/s00259-019-04485-331440799) ; Ahmadzadehfar H, Essler M. Predictive factors of response and overall survival in patients with castration-resistant metastatic prostate cancer undergoing (177)Lu-PSMA therapy. J Nucl Med. 2018;59:1033–4. https://doi.org/10.2967/jnumed.118.209270 . (PMID: 10.2967/jnumed.118.20927029653975)
- Contributed Indexing: Keywords: Predictive factors; Prognosis; Radioligand therapy; Response to therapy; [177Lu]Lu-PSMA
- Substance Nomenclature: 0 (Dipeptides) ; 0 (Heterocyclic Compounds, 1-Ring)
- Entry Date(s): Date Created: 20210307 Date Completed: 20211019 Latest Revision: 20220315
- Update Code: 20231215
- PubMed Central ID: PMC8484081
|